Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India

Evaluation of a Typhoid Conjugate Vaccine Introduction Program in Navi Mumbai, India

The purpose of this study is to evaluate the impact of a government-led typhoid conjugate vaccine introduction program on typhoid disease burden in Navi Mumbai, India.

Study Overview

• Status: Completed
• Conditions: Typhoid Fever; Enteric Fever; Salmonella Typhi Infection
• Intervention / Treatment: Biological: Typhoid Conjugate Vaccine

Detailed Description

A new generation of typhoid conjugate vaccines (TCVs) have been shown to be safe and provide long-lasting immunity in children. In India, Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) is manufactured by Bharat Biotech International Limited (BBIL). Immunogenicity studies by BBIL showed >90% detectable antibodies to Typbar TCV vaccine at 42 days and >70% at 720 days in persons 2-45 years old. A single dose of vaccine was effective in children 6-23 months old with 98% seroconversion at 42 days and persistent high antibody titers at 720 days. Another randomized controlled trial study by University of Oxford tested Vi-TT with a human challenge model of typhoid fever in which participants ingested Salmonella Typhi after vaccination. Typhoid fever was diagnosed by clinical criteria and/or positive blood culture at 2 weeks in 77% of controls (n=31) as compared to 35% in the Vi-TT group (n=37) to give vaccine efficacy of 54% (95% confidence interval of 26-71). Typbar TCV has been licensed in India for children >6 months old since 2013 and is currently used in the private sector. In January 2018, the World Health Organization (WHO) recommended the use of typhoid conjugate vaccines especially in those countries with the highest burden of disease and the highest burden of antimicrobial resistance. However, there are no field effectiveness studies yet for Typbar TCV.

In this study, a hybrid facility- and community-based typhoid surveillance strategy will be used to evaluate the impact of a government-led typhoid conjugate vaccine introduction program on typhoid disease burden in Navi Mumbai, India. Navi Mumbai is a metropolitan area extending from Mumbai with approximately 1.4 million people and wide demographic and socioeconomic strata, including slums. Navi Mumbai is comprised of 13 area nodes, and 8 of these nodes are under the jurisdiction of the local government body, Navi Mumbai Municipal Corporation (NMMC). Navi Mumbai has high enteric fever burden: a 2008 study found 98 blood culture-confirmed pediatric cases over 16 months in 2 hospitals with a majority of isolates exhibiting multi-drug resistance. Data from one private laboratory in 2015 showed over 225 S. Typhi cases including 3 cases with ceftriaxone resistance.

NMMC has decided to introduce TCV into public sector routine immunization services and will vaccinate all children 9 months to <15 years old within its jurisdiction - estimated 390,000 children - with TCV over 2 years. NMMC government officials are collaborating with researchers from WHO India, Institute of Cholera and Enteric Diseases (NICED), Centers for Disease Control and Prevention (CDC), and Stanford University to implement the TCV introduction in a two-phase cluster-randomized program in order to allow rigorous evaluation of population impact. NMMC has 22 urban health posts (UHPs) that give routine childhood immunizations. UHPs were first grouped into 3 strata based on % of population living in slums: low, medium, or high. Half of the UHPs within each stratum were then randomly selected to receive TCV in 2018 (Phase 1) and the remaining UHPs to receive TCV one year later in 2019 (Phase 2).

Evaluation studies of NMMC's TCV introduction program include: impact on blood-culture confirmed typhoid fever; impact on clinical syndromes of febrile illness; vaccine safety; vaccine efficacy; vaccination campaign coverage and acceptability surveys; environmental water contamination with Salmonella Typhi; seroconversion associated with typhoid infection; and cost-effectiveness of typhoid conjugate vaccination campaign.

• Study Type: Observational
• Enrollment (Actual): 17292

Contacts and Locations

Study Locations

• India
  • Navi Mumbai, India
    • D. Y. Patil Medical College and Hospital, Nerul
  • Navi Mumbai, India
    • Dr. Joshi's Central Clinical Microbiology Laboratory, Vashi
  • Navi Mumbai, India
    • Dr. Yewale Multispecialty Hospital for Children, Vashi
  • Navi Mumbai, India
    • Mahatma Gandhi Memorial (MGM) New Bombay Hospital, Vashi
  • Navi Mumbai, India
    • Mathadi Hospital Trust, Koparkharaine
  • Navi Mumbai, India
    • Navi Mumbai Municipal Corporation (NMMC) General Hospital, First Referral Unit (FRU), Vashi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 months to 14 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The focus of this study is children age 6 months to 16 years living in areas governed by Navi Mumbai Municipal Corporation (NMMC). The age range of children eligible to receive typhoid conjugate vaccine (TCV) in NMMC's TCV introduction program is 9 months to 15 years. For community surveys, only households with children <16 years old will be selected.

The evaluation study will examine a slightly broader age range than NMMC's TCV vaccination program because TCV is licensed for >6 month old children and because the vaccine introduction will occur over 1 year thus the oldest eligible children will be 16 years old at study end.

Description

Inclusion Criteria:

For overall study,

1. For hospital-based surveillance, children age 6 months to 16 years.
2. For community-based surveys, adult members of households with children <16 years old.
3. Parental consent (and child assent for >12 years) given.

For hospital-based surveillance for typhoid fever, additional criteria include: history of fever for >72 hours within the last 7 days without upper respiratory tract symptoms and vesicular rash; strong clinical suspicion of enteric fever including ileal perforations; or diagnosis of enteric fever confirmed by positive blood cultures or histopathology. For outpatients, additional criterion of living in areas governed by Navi Mumbai Municipal Corporation.

For hospital-based surveillance of adverse events of special interest, timing will focus on one month prior to and 42 days after the vaccination campaign. Diagnoses included are: anaphylaxis, bronchospasm, urticaria, Guillain-Barré syndrome, meningitis, encephalitis, myelitis, seizures, thrombocytopenia, and sudden death.

For all community surveys, additional criterion of living in areas governed by Navi Mumbai Municipal Corporation.

Exclusion Criteria:

For all study components,

1. Already enrolled in same study component.
2. No informed consent or assent given.

For hospital-based surveillance for typhoid fever, additional exclusion criteria are: fever <72 hours, symptoms of upper respiratory tract infection (coryza, rhinorrhea), and vesicular exanthem. For outpatients, those living outside of NMMC-governed areas will be excluded.

For community surveys, households without children <16 years old and households in which there is no adult (>18 years old) at time of survey will be excluded.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Phase 1: TCV in 2018; Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.	Biological: Typhoid Conjugate Vaccine; Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
Phase 2: TCV in 2019; Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.	Biological: Typhoid Conjugate Vaccine; Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
blood culture-confirmed typhoid fever	Hospital surveillance for typhoid fever diagnosed by blood cultures will be conducted at 6 study sites in Navi Mumbai: 5 hospitals and 1 independent laboratory.	up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events following immunization	Evaluation of safety and adverse events following immunization (AEFI) during Phase I of TCV introduction in 2018. Three safety evaluations include: 1) routine national AEFI surveillance system reports, 2) active follow-up by phone of a subset of vaccine recipients at 48hrs and 7 days post vaccination, and 3) hospital-based surveillance at 5 hospital study sites conducting typhoid fever surveillance examining patient records for adverse events of special interest in both vaccinated and unvaccinated populations	up to 4 months
vaccination coverage	Community surveys estimating TCV coverage achieved by the vaccination campaign in the public sector during phase 1 (and potentially phase 2 if funding allows) as well as vaccine acceptability, refusals, knowledge, attitudes, and social mobilization strategies.	up to 18 months
environmental water contamination with Salmonella Typhi	Molecular testing of household and municipal water samples for presence of Salmonella Typhi and Paratyphi A and impact of TCV vaccination program on water contamination.	up to 24 months
seroconversion associated with typhoid infection	Collect dried blood spots in subset of household surveys and store for future testing of antibodies associated with typhoid infection (once other research studies on best antibody tests have resulted).	up to 24 months
cost-effectiveness of typhoid conjugate vaccination campaign	Plan to develop a tool and to estimate the delivery cost of TCV, to estimate the cost of illness (COI) related to typhoid fever, and ultimately to estimate the cost-effectiveness of typhoid conjugate vaccination campaign conducted in Navi Mumbai.	up to 24 months
clinical syndromes of febrile illness	Community-based surveys of clinical syndromes of febrile illness and healthcare utilization in NMMC-governed areas (same as TCV vaccination areas).	up to 18 months

Collaborators and Investigators

• Sponsor: Stanford University
• Collaborators: Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention; World Health Organization; National Institute of Cholera and Enteric Diseases, India
• Investigators: Principal Investigator: Kashmira Date, MD MPH, Centers for Disease Control and Prevention; Principal Investigator: Shanta Dutta, MD PhD, National Institute of Cholera and Enteric Diseases (NICED); Principal Investigator: Pankaj Bhatnagar, MD, World Health Organization (WHO) - India

Study record dates

Study Major Dates

• Study Start (Actual): July 2, 2018
• Primary Completion (Actual): March 31, 2021
• Study Completion (Actual): March 31, 2021

Study Registration Dates

• First Submitted: May 30, 2018
• First Submitted That Met QC Criteria: May 30, 2018
• First Posted (Actual): June 13, 2018

Study Record Updates

• Last Update Posted (Actual): October 4, 2021
• Last Update Submitted That Met QC Criteria: September 30, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Body Temperature Changes; Enterobacteriaceae Infections; Salmonella Infections; Fever; Typhoid Fever
• Other Study ID Numbers: IRB-39627; OPP1169264 (Other Grant/Funding Number: Bill and Melinda Gates Foundation)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No